Abhimanyu Verma Sells 5,285 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,285 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50. Following the completion of the sale, the chief technology officer owned 192,171 shares of the company’s stock, valued at approximately $980,072.10. The trade was a 2.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Up 1.3%

SOPH opened at $5.51 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company’s 50-day moving average is $5.15 and its 200 day moving average is $4.97. SOPHiA GENETICS SA has a fifty-two week low of $2.92 and a fifty-two week high of $6.30. The firm has a market capitalization of $462.23 million, a P/E ratio of -10.60 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently added to or reduced their stakes in SOPH. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at about $50,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.50.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were reported as pre-planned Rule 10b5-1 transactions tied to equity vesting and tax withholding, suggesting they may be administrative rather than a reflection of weakening business fundamentals.
• Neutral Sentiment: Several insiders sold shares in the same short period, including the chairman, CEO, CFO, and other executives, which keeps investor focus on insider activity. Article Title
• Negative Sentiment: A heavy run of insider selling can still pressure shares near term because some investors may interpret it as reduced confidence or increased stock supply.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.